Skip to main content
Log In
Alger
  • About Alger
    • Our History
      Our Investment Approach
      Investment Team
      Careers
      Commitment to Sustainability
      Commitment to Culture & Employees
      Charitable Giving
      We Remember
  • Strategies
    • Strategies Overview
      Asset Classes
      Vehicles
      Strategy Finder
      Think Further For Retirement
      Large Cap
      Mid Cap
      Small/SMid Cap
      International
      Alternatives
      Specialty
      Focus
      Mutual Funds
      ETFs
      SMAs
      Institutional Separate Accounts
      UCITS
      Collective Investment Trusts
  • Insights
    • Insights
      Blogs
      Alger On the Money
      Alger On the Record
      Manager Commentary
      Capital Markets Outlook
      Retirement Solutions
      Viewpoints
      The Power of Focus
  • Newsroom
    Press ReleasesIn the News
  • Contact Us
AlgerOn theMoney
.st0 { fill: #999999; } Explore Insights .st0 { fill: #999999; } Subscribe to Emails .st0 { fill: #999999; } .st0 { fill: #999999; } Download PDF

Doctor's Orders

Advancements in surgical procedures owing to innovation in bioengineering and biomaterials continue to shift physicians and patients towards minimally invasive procedures. Will improved outcomes for patients create favorable opportunities for companies?

Advancements in surgical procedures owing to innovation in bioengineering and biomaterials continue to shift physicians and patients towards minimally invasive procedures. Will improved outcomes for patients create favorable revenue opportunities for innovative companies?​​​​


​​​​Global Minimally Invasive Surgical Systems Market​​​​​
​​​
​​​​
  • Minimally invasive surgery (“MIS”) enables doctors to use methods that limit the size and number of incisions during surgeries, making them relatively safer than open medical surgeries. Moreover, doctors can also use minimally invasive procedures to diagnose and treat various types of diseases.​
  • According to Statista, the global MIS systems market is expected to reach $55.6 billion by 2030, resulting in a compounded annual growth rate (CAGR) of 7.8%. We believe this growth is primarily driven by increasing prevalence of diseases such as cancers and stomach related issues, along with common elected procedures like hip and knee replacements.
  • Furthermore, in 2021 the U.S. Centers for Disease Control announced that heart disease was now the leading cause of death in the U.S., where 18.2 million adults suffer from a coronary artery disease. In our view, increasing demand for surgeries tied to cardiovascular disease, coupled with awareness around the benefits of early detection, should contribute to MIS market growth. We believe companies tied to this space may offer a compelling investment opportunity over the next decade.

Recommended Insights for You:

​​
​​​The views expressed are the views of Fred Alger Management, LLC (“FAM”) and its affiliates as of November ​2022. These views are subject to change at any time and may not represent the views of all portfolio management teams. These views should not be interpreted as a guarantee of the future performance of the markets, any security or any funds managed by FAM. These views are not meant to provide investment advice and should not be considered a ​recommendation to purchase or sell securities. ​​Alger pays compensation to third party marketers to sell various strategies to prospective investors. ​

​​ Risk Disclosures: Investing in the stock market involves certain risks, including the potential loss of principal.​ Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies’ earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as war, acts of terrorism, the spread of infectious illness such as COVID-19 or other public health issues, recessions, or other events could have a significant impact on investments. Past performance is not indicative of future performance.​ Investors whose reference currency differs from that in which the underlying assets are invested may be subject to exchange rate movements that alter the value of their investments.

This information is general in nature and should not be construed as legal or tax advice. Alger makes no warranties with regard to such information or the results obtained by its use. Alger disclaims any liability arising out of your use of, or any tax position, taken in reliance on such information. Always consult an attorney or qualified tax professional regarding your specific legal or tax situation.
​
​​Important Information for US Investors: This material must be accompanied by the most recent fund fact sheet(s) if used in connection with the sale of mutual fund and ETF shares. Fred Alger & Company, LLC serves as distributor of the Alger mutual funds ​

Important Information for UK and EU Investors: This material is directed at investment professionals and qualified investors (as defined by MiFID/FCA regulations). It is for information purposes only and has been prepared and is made available for the benefit in​vestors. This material does not constitute an offer or solicitation to any person in any jurisdiction in which it is not authorised or permitted, or to anyone who would be an unlawful recipient, and is only intended for use by original recipients and addressees. The original recipient is solely responsible for any actions in further distributing this material and should be satisfied in doing so that there is no breach of local legislation or regulation. ​

​Certain products may be subject to restrictions with regard to certain persons or in certain countries under national regulations applicable to such persons or countries.

​Alger Management, Ltd. (company house number 8634056, domiciled at 78 Brook Street, London W1K 5EF, UK) is authorised and regulated by the Financial Conduct Authority, for the distribution of regulated financial products and services. FAM and/or Weatherbie Capital, LLC, U.S. registered investment advisors, serve as sub-portfolio manager to financial products distributed by Alger Management, Ltd.

Alger Group Holdings, LLC (parent company of FAM and Alger Management, Ltd.), FAM, and Fred Alger & Company, LLC are not authorized persons for the purposes of the Financial Services and Markets Act 2000 of the United Kingdom (“FSMA”) and this material has not been approved by an authorized person for the purposes of Section 21(2)(b) of the FSMA.
​
Important Information​ for Investors in Israel: This material is provided in Israel only to investors of the type listed in the first schedule of the Securities Law, 1968 (the “Securities Law”) and the Regulation of Investment Advice, Investment Marketing and Investment Portfolio Management Law, 1995. The Fund units will not be sold to investors who are not of the type listed in the first schedule of the Securities Law.
​
Statista is a German company specializing in market and consumer data. According to the company, its platform contains more than 1,000,000 statistics on more than 80,000 topics from more than 22,500 sources and 170 different industries.​​​​

​Alger pays compensation to third party marketers to sell various strategies to prospective investors.

Fre​d Alger & Company, LLC 100 Pearl Street, New York, NY 10004 / www.alger.com​
​ 800.305.8547 (Retail) / 800.223.3810 (Institutional)​

​
​
​
​
​
​
​

RecommendedContent Title

ETF Investors

This ETF is different from traditional ETFs.

Traditional ETFs tell the public what assets they hold each day. This ETF will not. This may create additional risks for your investment. Specifically:

You may have to pay more money to trade the ETF’s shares. This ETF will provide less information to traders, who tend to charge more for trades when they have less information.

The price you pay to buy ETF shares on an exchange may not match the value of the ETF’s portfolio. The same is true when you sell shares. These price differences may be greater for this ETF compared to other ETFs because it provides less information to traders.

These additional risks may be even greater in bad or uncertain market conditions.

The differences between this ETF and other ETFs may also have advantages. By keeping certain information about the ETF confidential, this ETF may face less risk that other traders can predict or copy its investment strategy. This may improve the ETF’s performance. If other traders are able to copy or predict the ETF’s investment strategy, however, this may hurt the ETF’s performance. For additional information regarding the unique attributes and risks of this ETF, please refer to the prospectus.

ABOUT ALGER

  • Our History
  • Our Investment Approach
  • Investment Team
  • Careers
  • Charitable Giving
  • We Remember
  • Think Further
  • Documents & Forms
  • Fund Literature
  • FAQs

ESG

  • Commitment to Sustainability
  • Alger's Approach to ESG Investing and Oversight
  • Weatherbie’s Approach to ESG Investing and Oversight
  • Redwood's Approach to Responsible Investing
  • Commitment to Culture & Employees

ASSET CLASSES

  • Large Cap
  • Mid Cap
  • Small/SMid Cap
  • International
  • Alternatives
  • Specialty
  • Focus

VEHICLES

  • Mutual Funds
  • ETFs
  • SMAs
  • Institutional Separate Accounts
  • UCITS
  • Collective Investment Trusts

TOOLS

  • Strategy Finder
  • 10 Year Estimator
  • Quarterly Expense Estimator

INSIGHTS

  • Featured Insights
  • Capital Markets Outlook
  • Alger On the Money
  • Alger On the Record
  • The Alger Podcast
  • Think Further for Retirement
  • Search All Insights

NEWSROOM

  • Press Releases
  • In the News

LITERATURE

  • Mutual Funds
  • SMAs
  • Institutional Separate Accounts
  • UCITS

CONTACT US

  • All Inquiries

LEGAL NOTICES

  • Proxy Information
  • 2025 Dividends & Distribution Information
  • Sales Charges
  • Customer Relationship Summaries
  • UK Investor Report
  • Form ADVs
View Mobile Site

Copyright Alger All Rights Reserved Privacy Policy Business Continuity Terms and Conditions
youtube channel LinkedIn Instagram